<DOC>
	<DOCNO>NCT02089347</DOCNO>
	<brief_summary>The aim study generate additional safety immunogenicity data support registration product Japan . Primary objective : - To demonstrate non-inferiority SP306 versus DT ( DT BIK® 0.1mL ) vaccine term diphtheria tetanus booster response rate ( proportion subject booster response ) seroprotection rate ( percentage subject antitoxin concentration ≥0.1 IU/mL ) 28 day ( window 28-35 day ) one injection Japanese adolescent 11-12 year age . - To evaluate immune response SP306 pertussis antigens PT FHA term booster response rate ( proportion subject booster response ) 28 day ( window 28-35 day ) one injection Japanese adolescent 11-12 year age . Secondary objective : - To evaluate immune response study vaccine diphtheria , tetanus pertussis antigen . - To assess safety study vaccine one injection Japanese adolescent 11-12 year age .</brief_summary>
	<brief_title>Study SP306 Given Intramuscularly Compared DT BIK® Given Subcutaneously Japanese Adolescents 11 - 12 Years Old</brief_title>
	<detailed_description>Study participant receive either single dose SP306 vaccine intramuscularly dose DT BIK® vaccine subcutaneously . They monitor vaccination immediate adverse event ( AEs ) solicit injection site systemic reaction unsolicited AEs include serious adverse event throughout study period , approximately 28 day ( +7 day ) .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 11 12 year consider healthy day inclusion Informed consent form assent form sign dated parent ( ) / legal representative ( ) subject respectively Completed childhood vaccination diphtheria , pertussis tetanus ( i.e. , receive 4 dos Japaneseproduced DTaP vaccine ) , confirm check immunization record yet undergone additional DT vaccination Able attend schedule visit comply trial procedure For female subject , either premenarchal , postmenarchal negative urine pregnancy test . Any condition disease , opinion Investigator : would pose health risk subject might interfere ability participate fully study might interfere evaluation vaccine would otherwise make participation inappropriate accord Investigator 's clinical judgment History diphtheria , tetanus , pertussis , confirm either clinically , serologically , microbiologically Suspected know hypersensitivity vaccine component history life threaten reaction vaccine contain substance study vaccine Vaccination last 5 year tetanus , diphtheria , and/or pertussis Known suspect congenital immunodeficiency , current / previous acquire immunodeficiency , current / previous receipt immunosuppressive therapy anticancer chemotherapy radiation therapy , current / previous ( within last 6 month ) systemic corticosteroid therapy Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial inclusion Planned participation another clinical trial present trial period Receipt blood bloodderived product past 3 month , might interfere assessment immune response Receipt vaccine within 4 week precede trial vaccination , except influenza vaccination , may receive least 2 week study vaccine Planned receipt vaccine trial period Clinical known serological evidence systemic illness include Hepatitis B , Hepatitis C and/or Human Immunodeficiency Virus ( HIV ) infection At high risk diphtheria , tetanus pertussis infection trial Known pregnancy , positive urine pregnancy test Currently breastfeed child Known thrombocytopenia history thrombocytopenia Bleeding disorder , receipt anticoagulant 3 week precede inclusion History acute disseminate encephalomyelitis , encephalopathy , GuillainBarré Syndrome ( GBS ) , autoimmune disease Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction might interfere ability comply trial procedure Identified employee Investigator , study center , studyaffiliated vendor , Sponsor , direct indirect involvement propose study study direction Investigator study center ; identify spouse child ( whether natural adopt ) employee .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Tetanus</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Pertussis</keyword>
	<keyword>TdaP vaccine</keyword>
	<keyword>DT BIK®</keyword>
</DOC>